Clinical Trials
31 trialsSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
DG-03
AstraZeneca
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
LUCERNA
Astellas Pharma Inc
GLOW
Astellas Pharma Inc
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
DisTinGuish
Leap Therapeutics, Inc.
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
POWERRANGER
CancerCare Manitoba
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Odense University Hospital
MATRIX EG
Merck KGaA, Darmstadt, Germany
NEOMETRE
University of Campinas, Brazil
PREPARE
National Cancer Center, Korea
xeberecto
Institut Català d'Oncologia
AVAGAST
Genentech, Inc.
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
H. Lee Moffitt Cancer Center and Research Institute
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Ohio State University Comprehensive Cancer Center
XAGastric
Duke University
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
Stanford University
mXELOX
Sixth Affiliated Hospital, Sun Yat-sen University
GAST-TaxXel
University of Turku